Brief: Heartbeam Successfully Meets Clinical Endpoints In Pivotal Study For Its Groundbreaking 12-Lead ECG Synthesis Technology
29/04/2025 13:32
Heartbeam Inc BEAT.O: HEARTBEAM SUCCESSFULLY MEETS CLINICAL ENDPOINTS IN PIVOTAL STUDY FOR ITS GROUNDBREAKING 12-LEAD ECG SYNTHESIS TECHNOLOGY Source text: ID:nBw9HSrRHa Further company coverage: BEAT.O
Recent news on HeartBeam
See all newsBrief: Heartbeam Receives FDA Breakthrough Device Designation For Heart Attack Assessment
Brief: HeartBeam Will Not Build Large Commercial Organization For Arrhythmia Indication
Brief: Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock
HeartBeam, Inc. reports results for the quarter ended June 30 - Earnings Summary
HeartBeam Q2 loss per share narrows; co lowers FY net operating cash outflow guidance